Intragastric Balloon and Time-Restricted Eating for Weight Loss in Adults With Overweight or Obesity
Effects of Intragastric Balloon and Time-Restricted Intermittent Fasting Diet on Weight Loss and Metabolic Parameters in Adults With Overweight and Obesity
The goal of this non-randomized clinical study is to learn whether an intragastric balloon (IGB) and time-restricted eating (TRE; 16-hour daily fast with an 8-hour eating window), used alone or together, improve weight loss, body composition, and metabolic parameters in adults aged 18 to 65 years with overweight or obesity (body mass index 27.0 to 39.9 kg/m²). Participants are followed in four groups according to whether they have an IGB (placed as part of routine clinical care, not assigned by the study) and whether they choose to follow TRE: (1) standard nutrition therapy, (2) IGB plus standard nutrition therapy, (3) TRE plus standard nutrition therapy, and (4) IGB plus TRE plus standard nutrition therapy. All participants receive the same individualized energy-restricted diet, dietitian follow-up, behavioral education, and physical activity advice. Body weight and body composition are measured at baseline, 3 months, and 6 months; routine laboratory results are recorded at baseline and 6 months.
Visão geral do estudo
Status
Condições
Descrição detalhada
This is a prospective, single-center, non-randomized, exploratory (pilot) study with a 2×2 factorial structure. The two factors are intragastric balloon (IGB; present/absent) and time-restricted eating (TRE; yes/no). IGB placement is not a study procedure: it is performed as routine clinical care according to the physician's indication and the patient's preference, and the investigators have no role in that decision. TRE is offered in the dietetics outpatient clinic; participants who wish to follow it are allocated to the TRE groups, and those who do not are followed with standard nutrition therapy alone.
All groups receive the same frequency of dietitian visits, the same behavioral education, comparable energy targets, and the same physical activity advice (7,500 to 10,000 steps per day), so that groups differ only in IGB status and TRE. Body composition is measured by multi-frequency bioelectrical impedance analysis. Laboratory values are taken from routine clinical test results; no additional blood samples are drawn. Dietary intake is assessed with 3-day food records and physical activity with participants' smartphone step counters.
At least 15 participants per group (60 in total) are planned. Main and interaction effects of IGB and TRE will be analyzed with two-way analysis of variance or general linear models, and changes over time with repeated-measures analysis of variance or linear mixed models, adjusting for age, sex, baseline body mass index, comorbidities, physical activity, and energy intake.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Seher Şen, Assistant Professor
- Número de telefone: 05393919700
- E-mail: seherdalli@gmail.com
Locais de estudo
-
-
Yıldırım
-
Bursa, Yıldırım, Turquia (Türkiye)
- Recrutamento
- Yıldırım Doruk Hastanesi
-
Contato:
- Yıldırım Doruk Hastanesi Seher ŞEN, Assistant Professor
- Número de telefone: 05393919700
- E-mail: seher.sen@mudanya.edu.tr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 to 65 years
- Body mass index (BMI) 27.0 to 39.9 kg/m²; for BMI 27.0 to 29.9 kg/m², at least one obesity-related comorbidity (e.g., insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia)
- BMI of 27 kg/m² or higher for at least 2 years
- History of unsuccessful non-surgical weight-loss attempts
- Willingness to participate and written informed consent
Exclusion Criteria:
- Inflammatory bowel disease or other inflammatory conditions of the gastrointestinal tract (including esophagitis and hiatal hernia of 2 cm or larger)
- Previous gastrointestinal surgery
- History of upper gastrointestinal bleeding
- Gastroparesis
- Severe psychiatric illness
- Active malignancy
- Pregnancy or breastfeeding
- Alcohol or substance dependence
- Physical limitation preventing exercise
- Contraindication to intragastric balloon placement
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Standard Nutrition Therapy
Participants without an intragastric balloon who receive standard energy-restricted nutrition therapy only. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. |
|
Comparador Ativo: IGB + Standard Nutrition Therapy
Participants with an intragastric balloon (IGB) placed as part of routine clinical care who receive standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice. |
|
Experimental: TRE + Standard Nutrition Therapy
Participants without an intragastric balloon who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks. |
|
Experimental: IGB + TRE + Standard Nutrition Therapy
Participants with an intragastric balloon (IGB) placed as part of routine clinical care who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice. Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body weight
Prazo: Baseline, Month 3, Month 6
|
Kilograms, measured in light clothing without shoes (Tanita MC-780 MA) |
Baseline, Month 3, Month 6
|
|
Body mass index
Prazo: Baseline, Month 3, Month 6
|
Weight and height combined to report BMI in kg/m² |
Baseline, Month 3, Month 6
|
|
Percent total weight loss
Prazo: Month 3, Month 6
|
(Baseline weight - follow-up weight) / baseline weight × 100. |
Month 3, Month 6
|
|
Percent excess weight loss
Prazo: Month 3, Month 6
|
(Baseline weight - follow-up weight) / (baseline weight - ideal weight) × 100; ideal weight at BMI 25 kg/m². |
Month 3, Month 6
|
|
Fat mass
Prazo: Baseline, Month 3, Month 6
|
Kilograms, by multi-frequency bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Body fat percentage
Prazo: Baseline, Month 3, Month 6
|
Percent of body weight, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Muscle mass percentage
Prazo: Baseline, Month 3, Month 6
|
Percent of body weight, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Muscle mass
Prazo: Baseline, Month 3, Month 6
|
Kilograms, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fasting plasma glucose
Prazo: Baseline, Month 6
|
Concentration in mg/dL from routine clinical laboratory results |
Baseline, Month 6
|
|
fasting insulin (µIU/mL)
Prazo: Baseline, Month 6
|
Fasting serum insulin concentration in µIU/mL, obtained from routine clinical laboratory results. |
Baseline, Month 6
|
|
Glycated Hemoglobin (HbA1c)
Prazo: Baseline, Month 6
|
Glycated hemoglobin (HbA1c) as a percentage of total hemoglobin, obtained from routine clinical laboratory results. |
Baseline, Month 6
|
|
Total Cholesterol
Prazo: Baseline and Month 6
|
Serum total cholesterol concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
High-Density Lipoprotein (HDL) Cholesterol
Prazo: Baseline and Month 6
|
Serum HDL cholesterol concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Triglycerides
Prazo: Baseline and Month 6
|
Serum triglyceride concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Alanine Aminotransferase (ALT)
Prazo: Baseline and Month 6
|
Serum ALT activity in U/L, obtained from routine clinical laboratory results |
Baseline and Month 6
|
|
Aspartate Aminotransferase (AST)
Prazo: Baseline and Month 6
|
Serum AST activity in U/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Serum Iron
Prazo: Baseline and Month 6
|
Serum iron concentration in µg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Ferritin
Prazo: Baseline and Month 6
|
Serum ferritin concentration in ng/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Vitamin B12
Prazo: Baseline and Month 6
|
Serum vitamin B12 concentration in pg/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Folate
Prazo: Baseline and Month 6
|
Serum folate concentration in ng/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Sodium
Prazo: Baseline and Month 6
|
Serum sodium concentration in mmol/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Potassium
Prazo: Baseline and Month 6
|
Serum potassium concentration in mmol/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Daily energy intake
Prazo: Baseline and Month 6
|
Mean daily energy intake in kcal/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Protein Intake
Prazo: Baseline and Month 6
|
Mean daily protein intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Carbohydrate Intake
Prazo: Baseline and Month 6
|
Mean daily carbohydrate intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Fat Intake
Prazo: Baseline and Month 6
|
Mean daily fat intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Step Count
Prazo: Baseline and Month 6
|
Mean number of steps per day, reported by participants from their smartphone step counter. |
Baseline and Month 6
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MUDU-SBE-SS-06
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
In accordance with the study protocol approved by the ethics committee and national data protection legislation (Law No. 6698 on the Protection of Personal Data), individual participant data will be accessible only to the research team and will not be shared with third parties. Aggregate results will be published in peer-reviewed journals.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .